Perigon Wealth Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$976K Buy
36,954
+2,164
+6% +$63.4K 0.02% 544
2025
Q4
$1.01M Sell
34,790
-1,954
-5% -$58.6K 0.02% 543
2025
Q3
$1.02M Sell
36,744
-1,051
-3% -$26.6K 0.02% 497
2025
Q2
$920K Buy
37,795
+4,471
+13% +$98K 0.02% 493
2025
Q1
$692K Sell
33,324
-4,712
-12% -$118K 0.02% 536
2024
Q4
$922K Sell
38,036
-8,305
-18% -$204K 0.02% 464
2024
Q3
$1.19M Sell
46,341
-3,903
-8% -$99.4K 0.03% 391
2024
Q2
$1.18M Buy
50,244
+13,716
+38% +$346K 0.03% 336
2024
Q1
$1.05M Buy
36,528
+6,945
+23% +$209K 0.03% 359
2023
Q4
$971K Buy
29,583
+3,380
+13% +$91.9K 0.03% 344
2023
Q3
$730K Buy
26,203
+6,864
+35% +$224K 0.03% 367
2023
Q2
$659K Buy
19,339
+3,803
+24% +$120K 0.03% 390
2023
Q1
$467K Buy
15,536
+1,608
+12% +$49.8K 0.03% 409
2022
Q4
$393K Sell
13,928
-2,806
-17% -$89.1K 0.02% 448
2022
Q3
$550K Sell
16,734
-210
-1% -$7.71K 0.05% 313
2022
Q2
$534K Buy
16,944
+5,736
+51% +$201K 0.04% 319
2022
Q1
$515K Sell
11,208
-249
-2% -$11.9K 0.04% 353
2021
Q4
$702K Sell
11,457
-1,001
-8% -$69.2K 0.05% 274
2021
Q3
$931K Buy
12,458
+779
+7% +$65.4K 0.08% 211
2021
Q2
$1.08M Buy
11,679
+972
+9% +$82.6K 0.1% 185
2021
Q1
$950K Sell
10,707
-73
-0.7% -$7.24K 0.1% 189
2020
Q4
$1M Buy
10,780
+2,404
+29% +$192K 0.12% 145
2020
Q3
$534K Buy
8,376
+811
+11% +$47.5K 0.07% 209
2020
Q2
$395K Buy
7,565
+981
+15% +$42.1K 0.06% 222
2020
Q1
$219K Buy
+6,584
New +$220K 0.04% 286
2018
Q2
Sell
-2,770
Closed -$71K 256
2018
Q1
$71K Hold
2,770
0.03% 274
2017
Q4
$68K Buy
+2,770
New +$70.1K 0.03% 252

Other funds holding ARKG

Perigon Wealth Management's ARKG Position: Q1 2026 in Review

Perigon Wealth Management increased its ARK Genomic Revolution ETF (ARKG) stake by 6.2% in Q1 2026, buying an estimated $63.4K and bringing the position to 36,954 shares worth $976K. The position accounts for 0.02% of the portfolio, ranked #544.

Perigon Wealth Management first reported a position in ARKG in Q4 2017 and has held it in 27 quarters since. The position peaked at $1.19M in Q3 2024. 218 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.

  • Perigon Wealth Management held 36,954 shares of ARK Genomic Revolution ETF worth $976K as of Q1 2026.
  • Perigon Wealth Management bought 2,164 ARK Genomic Revolution ETF shares in Q1 2026, an estimated $63.4K.
  • ARK Genomic Revolution ETF made up 0.02% of Perigon Wealth Management's portfolio in Q1 2026, its #544 holding.
  • Perigon Wealth Management first reported a position in ARK Genomic Revolution ETF in Q4 2017 and has held it in 27 quarters since.
  • Perigon Wealth Management's ARK Genomic Revolution ETF position peaked at $1.19M in Q3 2024.
  • 218 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.

Based on Perigon Wealth Management's 13F filing for Q1 2026, filed 10 Apr 2026.